Balasa Dinverno & Foltz LLC raised its stake in Rockwell Medical, Inc. (NASDAQ:RMTI) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,300 shares of the company’s stock after buying an additional 3,000 shares during the period. Balasa Dinverno & Foltz LLC owned approximately 0.10% of Rockwell Medical worth $431,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in RMTI. KCG Holdings Inc. acquired a new position in shares of Rockwell Medical during the first quarter valued at approximately $111,000. Geneva Advisors LLC increased its stake in Rockwell Medical by 3.7% in the first quarter. Geneva Advisors LLC now owns 20,970 shares of the company’s stock valued at $131,000 after buying an additional 750 shares in the last quarter. American International Group Inc. increased its stake in Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock valued at $185,000 after buying an additional 1,955 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Rockwell Medical by 11.3% in the first quarter. Metropolitan Life Insurance Co. NY now owns 42,220 shares of the company’s stock valued at $264,000 after buying an additional 4,287 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in Rockwell Medical by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 78,948 shares of the company’s stock valued at $517,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 20.62% of the company’s stock.
Shares of Rockwell Medical, Inc. (RMTI) opened at 7.16 on Friday. Rockwell Medical, Inc. has a 12-month low of $3.55 and a 12-month high of $8.98. The company’s 50 day moving average is $7.79 and its 200 day moving average is $6.85. The company’s market capitalization is $372.73 million.
Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Tuesday, May 9th. The company reported ($0.09) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.09). The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $12.66 million. Rockwell Medical had a negative net margin of 36.35% and a negative return on equity of 36.36%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share. Analysts expect that Rockwell Medical, Inc. will post ($0.39) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/07/29/balasa-dinverno-foltz-llc-has-431000-stake-in-rockwell-medical-inc-nasdaqrmti.html.
Several research firms recently issued reports on RMTI. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. ValuEngine downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, BidaskClub downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Friday. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.50.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
